Today’s Solutions: October 19, 2021

A new study spearheaded by Professor Sarah Blagden and Dr. Hagen Schwenzer, researchers from the University of Oxford, in collaboration with biopharmaceutical company NuCana, has led to a novel chemotherapy drug that demonstrates significant potency in killing cancer cells.

The new drug, called NUC-7738, is an enhancement of a naturally-occurring nucleoside analog known as Cordycepin (or 3’deoxyadenosine) that is found in the Himalayan fungus Cordyceps Sinensis. This fungus has been used to treat cancers and other inflammatory diseases in traditional Chinese medicine for centuries, however, the drug is rapidly broken down in the bloodstream, rendering what’s left of it to be of minimal use once it reaches the tumor.

To improve the potency of Cordyceps Sinensis, NuCana developed Cordycepin into a clinical therapy, using the new ProTide technology, resulting in a chemotherapy drug with enhanced efficacy.

What is ProTech technology?

ProTech technology is a novel approach for delivering chemotherapy drugs into cancer cells by attaching small chemical groups to nucleoside analogs such as Cordycepin. These are later metabolized once it has reached the patient’s cancer cells, releasing the activated drug. ProTech technology has already been successfully used in FDA-approved drugs to treat infections like Hepatitis C, Ebola, and Covid-19.

The results

Based on the study published in Clinical Cancer Research, NUC-7738 is even more poisonous than Cordycepin to a range of cancer cells.

Currently, NUC-7738 is being assessed by Oxford researchers and partners in Edinburgh and Newcastle in Phase 1 clinical trial NuTide:701, where the drug is being tested on cancer patients with advanced solid tumors that didn’t respond well to conventional treatment. So far, the early results have demonstrated NUC-7738 promising anti-cancer activity and that the drug is well tolerated by patients.

Based on these encouraging results, Phase 2 clinical trials are in the works.

Source study: Clinical Cancer ResearchThe novel nucleoside analogue ProTide NUC-7738 overcomes cancer resistance mechanisms in vitro and in a first-in-human Phase 1 clinical trial

Solutions News Source Print this article
More of Today's Solutions

These are the inaugural winners of the Earthshot Prize

We recently wrote about Earthshot Prize nominee Vinisha Umashankar, a clever 14-year-old student from Tamil Nadu who created a mobile ironing cart that runs off solar power. Although Umashankar didn’t win an Earthshot Prize, the ... Read More

6 Ways to end bedtime procrastination

Are you a bedtime procrastinator? Do you know you should go to sleep but end up binge-watching television, scrolling through social media, or looking for an appetizer recipe to bring to that dinner party this ... Read More

Residents of this small Spanish town pay less taxes the more they recycle

The small Spanish town of La Nucía is located just 10 kilometers away from the touristy seaside resorts of Benidorm. But compared to its skyscraper-dominant neighbor, La Nucía’s architecture ranks high in sustainability rather than ... Read More

Help scientists locate walruses by becoming a walrus detective

The Arctic is under increasing threat due to climate change, and so is the biodiversity that it supports. That’s why the World Wildlife Fund for Nature and the British Antarctic Survey have decided to collaborate with ... Read More

EU is giving away 60,000 free Interrail tickets to European youth

The European Commission Vice President Margaritis Schinas realizes that the coronavirus pandemic forced young people to “[miss] valuable and formative moments of their youth.” As a recognition of their sacrifice in the name of public ... Read More

Shades of Favor is the first all-Black female group to summit Kilimanjaro

A team of climbers has made history as the first group of Black women to climb Mount Kilimanjaro, the world’s largest free-standing mountain. The group of nine women come from a wide range of backgrounds ... Read More